linjc16/ctgov huggingface dataset:
Percutaneous Vertebroplasty: Prophylactic Treatment of Adjacent Vertebra

Study Overview
=================
Brief Summary
-----------------
Percutaneous vertebroplasty is a treatment for painful osteoporotic compression fractures. Multiple reports have shown as high as 20 % refracturerates in vertebrae adjacent to those that have been treated with percutaneous vertebroplasty. The purpose of the study is to determine if prophylactic vertebroplasty of unfractured vertebrae adjacent to the treated fractured vertebrae can reduce the rates of refracture in adjacent vertebrae.

Official Title
-----------------
Percutaneous Vertebroplasty.Study of Refracture Rates After Prophylactic Vertebroplasty of Adjacent Vertebrae

Conditions
-----------------
Osteoporosis, Vertebral Fracture

Intervention / Treatment
-----------------
* Procedure: Percutaneous vertebroplasty


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: CT and MRI proven non healed painful osteoporotic compression fracture in the thoracic and lumbar spine. Exclusion Criteria: Infection High grade spinal stenosis Contraindications to MRI Dementia

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>50 osteoporotic patients with a vertebral insufficiency fracture will receive treatment of the vertebrae with standard vertebroplasty | Procedure: Percutaneous vertebroplasty<br>* PMMA injection 3-10 milliliter in each treated vertebrae<br>* Other names: PMMA;|
| Experimental: 2<br>50 osteoporotic patients with a vertebral insufficiency fracture will receive treatment of the vertebrae with standard vertebroplasty. The adjacent vertebrae will be treated with 3-5 ml of PMMA | Procedure: Percutaneous vertebroplasty<br>* PMMA injection 3-10 milliliter in each treated vertebrae<br>* Other names: PMMA;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Refracture rate based on MRI and CT after 3 months and one year |  | 3 months and one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain relief after the procedure based on VAS |  | 3 months and one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
osteoporosis, vertebroplasty, prophylactic, vertebrae, fracture
Endometrial Fluid Study in Natural Cycles: a Prospective Observational Study

Study Overview
=================
Brief Summary
-----------------
This study is designed to collect information about the characteristics of endometrial fluid at day 2 and day 4 post-ovulation in normal fertile women.

Detailed Description
-----------------
Implantation rates have stabilised around 35% in IVF and a current key rate limiting step is achieving successful implantation of the embryo. 1/3 of implantation failures are estimated to be caused by a problem with the receptivity of the endometrium. In recent years, several measurable parameters have been reported to assess endometrial receptivity. However, one parameter remains undescribed, the endometrial fluid viscosity. It is generally believed that the viscosity change post ovulation is influenced by the luteal phase endocrine milieu, and it is possible that the viscosity of the endometrial fluid has an impact on implantation.

Official Title
-----------------
Endometrial Fluid Study in Natural Cycles: a Prospective Observational Study

Conditions
-----------------
Endometrial Fluid

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: ≤ 35 years Women eligible and qualified for egg donation at IVIRMA Bilbao Proven fertile (having given birth to at least one spontaneously conceived normal child) Signed written consent including sharing of anonymized data Exclusion Criteria: Contraindications for egg donation according to IVIRMA Bilbao guidelines

Ages Eligible for Study
-----------------
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Day 2 post ovulation<br>Ultrasound of the endometrium, Endometrial fluid sample, Blood sample | |
| Day 4 post ovulation<br>Ultrasound of the endometrium, Endometrial fluid sample, Blood sample | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Viscosity of endometrial fluid at D2 and D4 post ovulation of the normal cycle, respectively |  | 4 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma progesterone level |  | 4 days | 
| Plasma estradiol (E2) level |  | 4 days | 
| Endometrial thickness as measured by ultrasound |  | 4 days |
Cocaine Effects in Humans: Physiology and Behavior - 1

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the effects of buprenorphine or methadone maintenance on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving, in opiate-dependent cocaine users.

Official Title
-----------------
Cocaine Effects in Humans: Physiology and Behavior

Conditions
-----------------
Cocaine-Related Disorders

Intervention / Treatment
-----------------
* Drug: Methadone


Participation Criteria
=================
Eligibility Criteria
-----------------
Please contact site for information.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Methadone|normal maintenance dose|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Interaction of cocaine and meds on cardio |  | 3 hr | 
| Interaction of cocaine & meds on coc's subjective |  | 3 hr | 
| Effects of medication on cocaine craving |  | 3 hr | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
self-administration
Restricted Reporting for Positive Urine Cultures

Study Overview
=================
Brief Summary
-----------------
Asymptomatic bacteriuria (AB) is a condition in which bacteria are detected in urine culture without urinary symptoms. The inappropriate use of antibiotic treatment for AB selects bacterial flora to express resistance mutations. Reducing inappropriate antibiotic use for AB is difficult, since the microbiology laboratory cannot distinguish patients with AB. The investigators study will use a restricted laboratory report requesting the physician to call the laboratory for culture results. The restricted report may reduce the rate of inappropriate treatment of AB.

Detailed Description
-----------------
Positive urine cultures during the study period will be randomized to restricted microbiology laboratory reporting or standard microbiology laboratory reporting. Physician or patient consent will not be collected. Patient records will be assessed by the investigator to determine if patients have AB or urinary tract infection. Physician antibiotic treatment decision in both groups will be collected.

Official Title
-----------------
Restricted Reporting for Positive Urine Cultures Randomized Controlled Trial

Conditions
-----------------
Bacteriuria, Urinary Tract Infection

Intervention / Treatment
-----------------
* Behavioral: Restricted Reporting


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: positive urine culture from inpatients at Health Sciences Centre or St. Clare's Mercy Hospital or outpatients during study period. Exclusion Criteria: pregnancy, antibiotic treatment at the time of urine collection, collection from an indwelling catheter, admission to long term care facility.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Restricted Reporting<br>Microbiology laboratory will report Positive urine cultures may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call 777-xxxx (researcher mobile phone) for identification and susceptibility results | Behavioral: Restricted Reporting<br>* An abbreviated version of the microbiology report indicating that growth is present and the physician should call the lab for further details if clinically important<br>|
| No Intervention: Standard Reporting<br>Microbiology laboratory will report identification and susceptibility results | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Number of Patients Receiving Appropriate Treatment | Sum of urinary tract infection treated and asymptomatic bacteriuria not treated | 72 hours from positive culture |
Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens

Study Overview
=================
Brief Summary
-----------------
The study is recruiting 50 patients initiating or switching to Atripla and comparing them to 250 individuals previously followed in a prospective study of HIV+ low income individuals recruited from homeless shelters, single room occupancy hotels and free meal food lines as part of the UCSF Reach Study. Adherence will be measured through monthly unannounced pill counts and electronic medication monitors.

Official Title
-----------------
Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens

Conditions
-----------------
HIV Infections, Adherence

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18+ years old; HIV+; Initiating Atripla within 6-months of recruitment; Lives in the Tenderloin, South of Market, or Mission District San Francisco; Capable of providing informed consent; and Willing to complete all study procedures. Exclusion Criteria: Intoxication, cognitive dysfunction or psychosis will preclude potential subjects from informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV, Treatment experienced
A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer

Study Overview
=================
Brief Summary
-----------------
This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer.

Official Title
-----------------
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 10 Mg Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Drug: Atrasentan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of prostate cancer. Rising PSA while on hormonal therapy or following surgical castration. Documented evidence of metastatic disease. Exclusion Criteria: Have received cytotoxic chemotherapy. Have received opioid or narcotic medications (such as codeine or morphine) or radiation for pain caused by your prostate cancer in the last 6 months.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Atrasentan|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary objective of this study is to evaluate safety and efficacy as measured by time-to-disease progression |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hormone-Refractory, Prostate Cancer
Clinical and Genetic Factors Associated With Psychotic Symptoms Among Cocaine Abusers

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to determine the clinical, genetic and environmental factors associated with the phenotype severe psychotic symptoms caused by cocaine.

Detailed Description
-----------------
The second purpose is to include gene x environment interaction and to analyse the factors associated with the presence or the absence of severe psychotic symptoms induced by cocaine.

Official Title
-----------------
Multicentric Descriptive Cross-sectional Study Evaluating Cocaine Users in Treatment Center

Conditions
-----------------
Cocaine-induced Psychotic Disorder During Intoxication

Intervention / Treatment
-----------------
* Other: Interviews
* Other: Blood sample
* Other: Hair sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Adults, cocaine users, who have signed an informed consent Exclusion criteria: Poor venous condition (for blood samples), specially protected people, non French speaking, people who refuse to sign the consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1: Cocaine users<br>Adults, cocaine users | Other: Interviews<br>* Interviews<br>Other: Blood sample<br>* Blood sample<br>Other: Hair sample<br>* Hair sample<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| causes and protective factors of Cocaine Induced Psychosis CIP | clinical data biologic data genetic data | up to one day after taking cocaine | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| gene, environment interactions associated with CIP | clinical and genetic data | up to one day after taking cocaine | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cocaine, Cocaine-induced psychosis, Genetic, Clinical, Biological
Fractional Laser Therapy and Dermabrasion for Scar Revision

Study Overview
=================
Brief Summary
-----------------
The goals of this study will be to compare the safety and efficacy of fractional photothermolysis (Fraxel) with dermabrasion when used for scar revision.

Detailed Description
-----------------
Post traumatic and post surgical scar resurfacing is a common reason for patient visits to dermatologists and plastic surgeons. The Fraxel Laser is a new FDA cleared treatment for textural irregularities of the skin. There have been no studies examining the efficacy of Fraxel specifically for scar resurfacing though it is being used in clinical practice as its clearance was given under hte umbrella of coagulation of soft tissue. Dermabrasion is the gold standard for scar resurfacing and provides the criterion against which Fraxel therapy should be measured.

Official Title
-----------------
A Comparison Evaluation of Fractional Laser Therapy an Dermabrasion for Scar Revision

Conditions
-----------------
Scar

Intervention / Treatment
-----------------
* Procedure: laser and standard diamond fraise dermabrasion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: post surgical or post traumatic scar on face or scalp age 18 or older able to read and comprehend English Willing to follow treatment schedule and post treatment care requirements signed informed consent form Fitzpatrick skin type I-III Exclusion Criteria: known photosensitivity taken any medications known to induce photosensitivity in previous three months taken accutane within past 12 months pregnant or nursing currently on topical or oral antibiotics immunocompromised status skin type IV or greater

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: laser and standard diamond fraise dermabrasion<br>laser and standard diamond fraise dermabrasion | Procedure: laser and standard diamond fraise dermabrasion<br>* standard dermabrasion, CO2 laser resurfacing<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| safety and efficacy of fractional photothermolysis | compare the safety and efficacy of fractional photothermolysis (Fraxel) with dermabrasion when used for scar revision. | Post Surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
post surgical or post traumatic scar on face or scalp
Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection

Study Overview
=================
Brief Summary
-----------------
Although Prostate Specific Antigen (PSA) is a useful marker for early detection of the prostate cancer, its specivity is not sufficient. Several PSA variations were defined in order to increase the specivity of the test, but they aren't much more effective than the PSA alone for detection of disease. In older studies reported that, serum and prostatic tissue zinc levels decreased in prostat cancer disease. In our study we aimed to establish the utility of serum zinc, PSA, free PSA/PSA (fPSA/tPSA), zinc/PSA, levels for early detection of the prostate cancer.

Official Title
-----------------
Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection

Conditions
-----------------
Prostate Cancer Detection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with LUTS and elevated serum PSA levels and/or suspicious rectal examination Exclusion Criteria: usage of zinc included drugs, older prostatic operations, older prostatic radiotherapy, older prostatic biopsies, chronic rectal diseases (anal fissure, hemorrhoid, etc..), PIN(prostatic intraepithelial neoplasia) and ASAP(atypical small acinar proliferation) in pathologic evaluation.
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| prostate cancer<br>prostate adenocarcinoma in pathologic evaluation | |
| control<br>benign prostatic diseases in pathologic evaluation | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assesment of Serum Zinc/PSA Ratio in Patients With Prostate Cancer and Benign Prostatic Diseases | Does the zinc/PSA ratio show statistically signifacant difference in patients with prostate cancer? | measurement of serum zinc and PSA levels are performed prior to transrectal prostat biopsy; pathologic evaluation of biopsy specimens are performed within 2-3 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prostate cancer, PSA, zinc, zinc/PSA
Propranolol for Treatment of Cocaine Addiction - 2

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and efficacy of propanolol in the early treatment of cocaine dependence.

Official Title
-----------------
Propranolol for Treatment of Cocaine Addiction

Conditions
-----------------
Cocaine-Related Disorders

Intervention / Treatment
-----------------
* Drug: Propranolol


Participation Criteria
=================
Eligibility Criteria
-----------------
Please contact site for information.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 49 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Propranolol|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Side effects |  |  | 
| Cocaine use |  |  | 
| Cocaine withdrawal |  |  | 
| Cocaine craving |  |  | 
| Mood and anxiety |  |  | 
| Clinical improvement |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cocaine